Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma

摘要

The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.

主权项

1. A method for the treatment of a mammal suffering from bronchial asthma consisting essentially of administering to the mammal in need thereof a therapeutically effective amount of:
i. one or more compounds general formula 1 having the structure: wherein R1=—H or —COCH3, R2=—H or —COCH3, or wherein R1 and R2 are covalently coupled to —CH2— comprising a five member ring with the structure: wherein R4=—H or —CH2—CH═CH2 or —CH2—CH2—CH3 wherein R5=—H or —CH2—CH═CH2; andwherein R6=—H or —CH2—CH═CH2; ii. one or more compounds with formula I having the structure: wherein R1=—H or —COCH3, R2=—H or —COCH3, or wherein R1 and R2 are covalently coupled to —CH2— comprising a five member ring with the structure: wherein R3=—H;wherein R4=—CH═CH2 or —CH2—CH3 or —CH═NOH or —CN or —CH═NOAc or —CH═CH—COOEt;wherein R5=—H or —CH2—CH═CH2;wherein R6=—H or —CH2—CH═CH2 wherein R=—H or —CH3; andwherein R8=—H or —CH3; iii. one or more compounds with formula II having the structure: wherein R1=—H or —COCH3, R2=—H or —COCH3, or wherein R1 and R2 are covalently coupled to —CH2— comprising a five member ring with the structure: wherein R3=—CH═CH2 wherein R4=—H or —CH2—CH═CH2 or —CH2—CH2—CH3;wherein R5=—H or —CH2—CH═CH2;wherein R6=—H or —CH2—CH═CH2;wherein R7=—H; andwherein R8=—H; andwherein the bronchial asthma is treated by IL-4 or IL-5 pathway inhibition.